SPRINGWORKS THERAPEUTICS INC To buy or not to buy the share? SWTX Analysis & Overview

Key metrics

Basic

Market capitalization

$3.5b

Enterprise Value

$3.3b

Net debt

positive

Cash

$287.9m

Shares outstanding

75.0m

Valuation (TTM | estimate)

P/E

- | -

P/S

16.1 | 10.6

EV/Sales

14.8 | 9.7

EV/FCF

negative

P/B

8.5

Financial Health

Equity Ratio

81.9%

Return on Equity

-53.7%

ROCE

-62.6%

ROIC

-

Debt/Equity

0.0

Financials (TTM | estimate)

Revenue

$219.7m | $334.1m

EBITDA

$-260.9m | $-183.3m

EBIT

$-264.7m | $-235.6m

Net Income

$-253.9m | $-210.4m

Free Cash Flow

$-185.6m

Growth (TTM | estimate)

Revenue

730.5% | 74.4%

EBITDA

26.9% | 33.3%

EBIT

26.3% | 15.3%

Net Income

25.1% | 18.5%

Free Cash Flow

24.2%

More

EPS

$-3.4

FCF per Share

$-2.5

Short interest

10.2%

Employees

368

Rev per Employee

$520.0k

SpringWorks Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

11 Analysts have issued a SpringWorks Therapeutics Inc forecast:

8x Hold

73%

3x Sell

27%

More details on Analyst Estimates Including Price Targets

11 Analysts have issued a SpringWorks Therapeutics Inc forecast:

Hold

73%

Sell

27%

Analyst Estimates with Stock Price Targets

Financial data from SpringWorks Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	220 220	731% 731% 100%
- Direct Costs	15 15	819% 819% 7%
Gross Profit	205 205	725% 725% 93%
- Selling and Administrative Expenses	273 273	28% 28% 124%
- Research and Development Expense	196 196	15% 15% 89%
EBITDA	-261 -261	27% 27% -119%
- Depreciation and Amortization	3.84 3.84	79% 79% 2%
EBIT (Operating Income) EBIT	-265 -265	26% 26% -121%
Net Profit	-254 -254	25% 25% -116%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

SpringWorks Therapeutics Inc Stock News

Neutral

GlobeNewsWire

●

9 days ago

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms – – EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –

Neutral

GlobeNewsWire

●

9 days ago

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms – – EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –

Neutral

Business Wire

●

27 days ago

Merck KGaA, Darmstadt, Germany Completes Acquisition of SpringWorks Therapeutics to Accelerate Sustainable Growth of its Healthcare Business

DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that it has closed the acquisition of SpringWorks Therapeutics, Inc., for an enterprise value of $3.4 billion (approximately €3 billion)*, following regulatory clearances and the fulfillment of other customary closing conditions. The definitive agreement between Merck K...

More SpringWorks Therapeutics Inc News

Company Profile

Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in applying a precision medicine approach to acquiring, developing and commercializing medicines. It focuses on developing drugs for underserved patient populations suffering from devastating rare diseases and cancer. Its pipeline include Nirogacestat, Mirdametinib and BGB-3245. The company was founded in August 2017 and is headquartered in Stamford, CT.

Head office	United States
CEO	Saqib Islam
Employees	368
Founded	2017
Website	www.springworkstx.com

SpringWorks Therapeutics Inc Stock

Key metrics

Is SpringWorks Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

SpringWorks Therapeutics Inc Stock Analysis

Dividends

??

High-Growth-Investing

HGI

??

Levermann

???

Analyst Opinions

Analyst Opinions

Financial data from SpringWorks Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Don't miss a Thing! We will send you all news about SpringWorks Therapeutics Inc directly to your mailbox free of charge.

SpringWorks Therapeutics Inc Stock News

Company Profile

Register for Free